Glucagon-like Peptide-1 (GLP-1) Agonists

GLP-1 Receptor Agonist

<section class="Section" data-sectioncode="34089-3"><a name="i4i_description_id_6aef134e-6452-449b-8a2c-88b07e6d6447"></a><a name="section-10"></a><p></p><h1>11 DESCRIPTION</h1><p class="First">VICTOZA contains liraglutide, an analog of human GLP-1 and acts as a GLP-1 receptor agonist. The peptide precursor of liraglutide, produced by a process that includes expression of recombinant DNA in <span class="Italics">Saccharomyces cerevisiae,</span> has been engineered to be 97% homologous to native human GLP-1 by substituting arginine for lysine at position 34. Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor. The molecular formula of liraglutide is C<span class="Sub">172</span>H<span class="Sub">265</span>N<span class="Sub">43</span>O<span class="Sub">51</span> and the molecular weight is 3751.2 Daltons. The structural formula (Figure 1) is:</p><div class="Figure"><a name="id1018"></a><img alt="Figure 1: Structural Formula of liraglutide" src="49f302f5-f315-48b8-83a4-6ca56f01fded-01.jpg"/></div><p><span class="Bold">Figure 1 Structural Formula of liraglutide </span></p><p>VICTOZA injection is a sterile, aqueous, clear, colorless or almost colorless solution for subcutaneous use.  Each 1 mL of VICTOZA solution contains 6 mg of liraglutide and the following inactive ingredients: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14 mg; phenol, 5.5 mg; and water for injection. VICTOZA has a pH of approximately 8.15, hydrochloric acid or sodium hydroxide may be added to adjust pH. Each pre-filled pen contains a 3 mL solution of VICTOZA equivalent to 18 mg liraglutide (free-base, anhydrous).</p></section>

Victoza

liraglutide

3 ML liraglutide 6 MG/ML Pen Injector

3 ML liraglutide 6 MG/ML Pen Injector [Victoza]

Psoriasis (PsO)

Psoriatic Arthritis (PsA)

Ankylosing Spondylitis (AS)

Nonradiographic Axial Spondyloarthritis

Taltz

Juvenile Idiopathic Arthritis

Hidradenitis Suppurativa (HS)

Cosentyx

Siliq

Tremfya

Crohn's Disease (CD)

Ulcerative Colitis (UC)

Stelara

Skyrizi

Ilumya

Migraine

Cluster Headache

Migraine Prevention

Emgality

Qulipta

Acute Migraine

Ubrelvy

Nurtec ODT

Vyepti

Aimovig

Ajovy

Breast Cancer: HR+ (HER2-)

Verzenio

Ibrance

Kisqali

Atopic Dermatitis (Eczema)

Cibinqo

Eucrisa

Asthma (injectable)

Asthma OCS Dependent

Nasal Polyposis

Eosinophilic Esophagitis (EoE)

Prurigo Nodularis

Dupixent

Opzelura

Adbry

NSCLC ALK+ OR ROS1+ Disease

Lorbrena

Alecensa

Alunbrig

NSCLC cMET Mutation

Xalkori

Rheumatoid Arthritis (RA)

Xeljanz

Uveitis

Graft Versus Host Disease (GVHD)

Orencia

COVID-19 Treatment

Alopecia Areata

Olumiant

Multiple Sclerosis (MS)

Secondary Progressive Multiple Sclerosis

Zeposia

Rinvoq

Entyvio

Victoza is a medication that mimics a natural hormone in the body to regulate blood sugar, insulin, and digestion. It is used in conjunction with diet and exercise to enhance blood sugar control in adults and children aged 10 and above with type 2 diabetes. Additionally, Victoza might lower the risk of heart issues in adults with both type 2 diabetes and heart disease, typically when other diabetes treatments have been ineffective. Notably, Victoza is not intended for treating type 1 diabetes.